Nanobiotix S.A. (NBTX) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Replimune Group (REPL) has outperformed Nanobiotix S.A. (NBTX) over the past year, gaining 183.9% versus a gain of 17.4%. Over five years, NBTX leads with a +92.0% price change compared with -56.2% for REPL. Nanobiotix S.A. is the larger company by market cap ($1.25 billion vs $1.24 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBTX | REPL |
|---|---|---|
| Share price | $24.62 | $13.20 |
| Market cap | $1.25B | $1.24B |
| 1-day change | -2.42% | -0.38% |
| YTD return | +6.49% | +35.80% |
| 1-year return | +17.41% | +183.87% |
| 5-year return | +92.04% | -56.22% |
| EPS (TTM) | $-1.23 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $57.14 | $16.33 |
| 52-week low | $14.78 | $1.50 |
| Distance from 52-week high | -56.91% | -19.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +118.85% | +47.73% |
| Average volume | 149.07K | 4.20M |
| Shares outstanding | 50.92M | 94.22M |
| Employees | 100 | 465 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed NBTX by 166.5 percentage points over the past year.
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Healthcare · Biotechnology · 100 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Healthcare · Biotechnology · 465 employees
NBTX vs REPL FAQ
Which is bigger, Nanobiotix S.A. or Replimune Group?
Nanobiotix S.A. (NBTX) is larger, with a market capitalization of $1.25B compared with $1.24B for Replimune Group (REPL).
Which stock has performed better over the past year, NBTX or REPL?
REPL returned +183.87% over the past 12 months, compared with +17.41% for NBTX (price return, excluding dividends). Past performance does not predict future results.
Are Nanobiotix S.A. and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.